Trial Profile
Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer harboring epidermal growth factor receptor mutations
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2013
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Nov 2013 New trial record